New research indicates that patients who discontinue popular weight-loss injections like semaglutide or tirzepatide tend to recover reduced body mass at a significantly accelerated pace than those who end conventional diet and exercise plans.
Research printed in a prominent medical journal points out that while obese people often shed substantial amounts of their total mass while using the jabs, the weight is regained at an average rate of 0.8 kg per month upon discontinuation.
"Users purchasing these medications must be cognizant of the risk of rapid rebound weight gain when the medication ends," warns researcher Dr. Susan Jebb.
This pace of regain implies a return to original mass within about a year and a half.
Comparing Approaches
The study, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of the injectable medications with older methods.
Researchers point out that people who shed pounds through diet and exercise usually see a more gradual weight regain—around 0.1 kg a month—once they finish.
Understanding the Quick Rebound
Doctors suggest the mode of action of the injections explains the amplified regain.
These medications copy a natural hormone called glucagon-like peptide-1, which helps regulate feelings of fullness.
"Long-term administration of GLP-1 levels several times higher than normal may cause the system to produce less of its endogenous GLP-1, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition expert.
"Withdrawal of this medication results in hunger is no longer kept in check, making excessive eating much more probable."
An Ongoing Issue?
The NHS advise the injections for individuals with weight-linked health risks, accompanied by recommended diet and exercise modifications.
Many experts argue that, given the high risk of weight regain, the therapy should be considered ongoing.
This perspective is supported by drug manufacturers, who note that the results "highlight the persistent character of obesity," similar to managing conditions like high blood pressure.
User Testimonies
People who have stopped the medication describe a powerful return of appetite.
"It felt as if something flipping and you become starving," described an individual.
This challenge is compounded if users have not developed permanent lifestyle or habit changes during therapy.
Widespread Adoption
Survey data indicate that millions of adults in the UK have used weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is greater among females than males.
- The 40s and 50s demographic shows the highest usage rates.
- Many obtain the medications through private prescriptions rather than the NHS.
In conclusion, clinicians emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a permanent cure and lasting health benefits likely depends on ongoing behavioural changes.
